Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

What Is The Present And Forecasted Size Of The Viral Hepatitis Market?

In recent times, the market size for viral hepatitis has seen a consistent upward trend. It is predicted to expand from $16.21 billion in 2024 and reach $16.77 billion in 2025, reflecting a compound annual growth rate (CAGR) of 3.4%. Factors contributing to this growth during the historical period include advancements in vaccine development, the implementation of blood screening programs, the propagation of antiviral drugs, as well as worldwide health initiatives.

The market size for viral hepatitis is anticipated to experience a consistent increase in the forthcoming years, reaching a value of $19.71 billion by 2029, with a Compound Annual Growth Rate (CAGR) of 4.1%. The expected growth during the forecast period can be linked to factors such as the accessibility of treatment, public health laws, combination therapies, and initiatives towards health equity. Significant trends predicted for this period consist of bespoke treatment plans, the usage of digital health tools, the application of artificial intelligence in monitoring disease, and the micro-elimination of hepatitis C.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13028&type=smp

What Underlying Factors Are Supporting The Viral Hepatitis Market Growth?

The growth of the viral hepatitis market is forecasted to be spurred by the increasing occurrence of hepatitis. Liver infections, caused by several infectious viruses and non-infectious substances, result in hepatitis which in turn can lead to numerous health complications. Viral hepatitis can be caused by Hepatitis viruses A, B, C, D and E, leading to liver inflammation and damage. To illustrate, the European Centre for Disease Prevention and Control, a health agency based in Sweden, reported in April 2024 that there were 28,855 cases of hepatitis B virus (HBV) infection across 30 EU/EEA Member States in 2022, marking a 78% rise compared to 16,187 cases in 2021. Furthermore, the case count in 2022, amounting to 28,420, equates to a crude rate of 8.5 cases per 100,000 individuals. Thus, the escalating incidence of hepatitis is anticipated to fuel the viral hepatitis market.

How Does The Viral Hepatitis Market Differ By Segment?

The viral hepatitismarket covered in this report is segmented –

1) By Disease Type: Hepatitis A; Hepatitis B; Hepatitis C; Other Disease Types

2) By Diagnosis: Liver Biopsy; Blood Tests; Imaging Tests; Other Diagnosis

3) By Treatment: Antiviral Drugs; Surgery; Vaccine; Immune Modulator Drugs; Other Treatments

4) By Route Of Administration: Oral; Parenteral; Other Routes Of Administration

5) By End-Users: Hospitals; Specialty Clinics; Homecare; Other End-Users

Subsegments:

1) By Hepatitis A: Acute Hepatitis A; Chronic Hepatitis A

2) By Hepatitis B: Acute Hepatitis B; Chronic Hepatitis B; Hepatitis B Carrier

3) By Hepatitis C: Acute Hepatitis C; Chronic Hepatitis C

4) By Other Disease Types: Hepatitis D; Hepatitis E

What New Opportunities Are Emerging From Trends In The Viral Hepatitis Market?

Firms in the viral hepatitis market are striving to improve and update their drugs’ manufacturing process to maintain their market position. The invention and enhancement of drugs enhance medical comprehension by providing insight into how diseases work and hastening the creation of new treatments. Gilead Sciences Inc., a biopharmaceutical company located in the US, revealed in November 2022 that the Food and Drug Administration (FDA) had given its endorsement for the supplemental new medicine application (sNDA) for Vemlidy (tenofovir alafenamide) 25 mg tablets, a once-daily treatment for chronic hepatitis B virus (HBV) infection in children aged 12 years and above with compensated liver disease. The approval of Vemlidy for this group of pediatric patients was backed by the results of the 24-week Phase 2 clinical trial.

Who Are The Global Leaders Steering The Viral Hepatitis Market Forward?

Major companies operating in the viral hepatitis market are Pfizer Inc., Johnson & Johnson Co, F Hoffmann-La Roche AG, Merck & Co., AbbVie Inc., Novartis AG, Sanofi SA, Bristol-Myers Squibb, Astra Zeneca Pharmaceuticals LP, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Daiichi Sankyo Co. Ltd., Hetero Drugs Ltd., Eisai Co. Ltd., Boehringer Ingelheim Group, Sun Pharmaceutical Industries Ltd., Lupin Limited, Dr. Reddy’s Laboratories, Zydus Lifescience Ltd., Glenmark Pharmaceuticals Ltd., Cipla Ltd., Torrent Pharmaceuticals Ltd., Otsuka Pharmaceutical Co. Ltd., Wockhardt Ltd.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/viral-hepatitis-global-market-report

Which Region Is Likely To Register The Fastest Growth In The Viral Hepatitis Market?

North America was the largest region in the viral hepatitis market in 2024. The regions covered in viral hepatitis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=13028&type=smp

Browse Through More Reports Similar to the Global Viral Hepatitis Market 2025, By The Business Research Company

Liver Diseases Therapeutics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/liver-diseases-therapeutics-global-market-report

Liver Cancer Diagnostics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/liver-cancer-diagnostics-global-market-report

Human Liver Model Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/human-liver-model-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model